Table 2. Characteristics of patients with I-A, I-CF, and I-X genetic signatures.
| I-A | I-CF | I-X | p Value* | |
|---|---|---|---|---|
| Age (mean ± S.D., years) | 34 ± 7 | 44 ± 11 | 54 ± 15 | <0.001 |
| (median, years) | 33 | 46 | 56 | |
| Gender (% male) | 56 | 54 | 65 | 0.33 |
| Survival (median, months) | 51 | 96 | 13 | <0.001 |
| All Cases (n=199) | 59 (29.6) | 39 (19.6) | 101 (50.8) | |
| Astrocytomas (n=148) | 48 (32.4) | 3 (2.0) | 97 (65.6) | |
| Oligodendrogliomas (n=44) | 7 (15.9) | 34 (77.3) | 3 (6.8) | |
| Mixed Histology (n=7) | 4 (57.1) | 2 (28.6) | 1 (14.3) | |
| Grade II (n=31) | 15 (48.4) | 12 (38.7) | 4 (12.9) | |
| Grade III (n=69) | 34 (49.3) | 25 (36.2) | 10 (14.5) | |
| Grade IV (n=99) | 10 (10.1) | 2 (2.0) | 87 (87.9) | |
| Secondary GBM (n=12) | 7 (58.3) | 0 (0.0) | 5 (41.7) | |
| IDH Mutant Tumors (n=111) | 59 (53.2) | 39 (35.1) | 13 (11.7) | |
The 199 patients analyzed above are the subset of all adult (>20 yr) grade II-IV glioma patients who had age and survival information
*
One-way ANOVA for difference in mean age distribution, Chi-squared test for difference in gender proportions, and log-rank test for difference in survival